Company Quick10K Filing
Protalex
10-Q 2018-08-31 Filed 2018-10-12
10-K 2018-05-31 Filed 2018-09-11
10-Q 2018-02-28 Filed 2018-04-13
10-Q 2017-11-30 Filed 2018-01-10
10-Q 2017-08-31 Filed 2017-10-11
10-K 2017-05-31 Filed 2017-08-23
10-Q 2017-02-28 Filed 2017-04-05
10-Q 2016-11-30 Filed 2017-01-12
10-Q 2016-08-31 Filed 2016-10-17
10-K 2016-05-31 Filed 2016-07-15
10-Q 2016-02-29 Filed 2016-04-12
10-Q 2015-11-30 Filed 2016-01-07
10-Q 2015-08-31 Filed 2015-10-13
10-K 2015-05-31 Filed 2015-07-14
10-Q 2015-02-28 Filed 2015-04-10
10-Q 2014-11-30 Filed 2015-01-09
10-Q 2014-08-31 Filed 2014-10-08
10-K 2014-05-31 Filed 2014-08-05
10-Q 2014-02-28 Filed 2014-04-14
10-Q 2013-08-31 Filed 2013-10-11
10-Q 2013-02-28 Filed 2013-04-15
10-Q 2012-11-30 Filed 2013-01-11
10-Q 2012-08-31 Filed 2012-10-12
10-K 2012-05-31 Filed 2012-08-29
10-Q 2012-02-29 Filed 2012-04-05
10-Q 2011-11-30 Filed 2012-01-12
10-Q 2011-08-31 Filed 2011-09-28
10-K 2011-05-31 Filed 2011-08-19
10-Q 2011-02-28 Filed 2011-04-12
10-Q 2010-11-30 Filed 2011-01-10
10-Q 2010-08-31 Filed 2010-10-12
10-K 2010-05-31 Filed 2010-08-27
10-Q 2010-02-28 Filed 2010-04-07
10-Q 2009-11-30 Filed 2010-01-08
8-K 2018-11-30 Officers, Other Events, Exhibits
8-K 2018-02-28 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits

Protalex Financials

PRTX Metrics, Comps, Filings

Quarterly | Annual

Business

We are focused on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases including rheumatoid arthritis (RA) and Immune Thrombocytopenia (ITP). Our lead product candidate, PRTX-100, a new generation immunomodulatory therapy, is a highly-purified form of Staphylococcal protein A, which is a bacterial protein known to modify aspects of the human immune system. PRTX-100 has demonstrated effectiveness in animal models of autoimmune diseases and has demonstrated activity on cultured human immune cells at very low concentrations, although the effectiveness of PRTX-100 shown in pre-clinical studies using animal models may not be predictive of the results that we would see in future human clinical trials. The safety, tolerability and pharmacokinetics (PK) of PTRX-100 in humans have now been characterized in eight clinical studies and was granted Orphan Drug Designation (ODD) in the United States and Europe for the treatment of ITP.

We do not anticipate generating operating revenue for the foreseeable future and do not currently have any products that are marketable. In order to continue our research and development program and commercialization efforts we will require substantial additional working capital. We currently have no agreements, commitments or understandings with respect to raising the working capital necessary to continue our research and development program and commercialization efforts. Although we are exploring all options to raise working capital, if we are not successful in imminently raising additionally working capital, we will be forced to substantially scale back, suspend or discontinue operations.

In March 2015, the FDA accepted our Investigational New Drug (IND) application for a Phase I/II open-label, dose-escalating study of PRTX-100 in adults with persistent/chronic ITP (the “PRTX-100-202 Study”). In June 2015, the U.S. Food and Drug Administration (FDA) granted ODD to PRTX-100 for the treatment of ITP. In July 2015, the European Medicines Agency (EMA) granted approval for a Phase 1b open-label, dose-escalating study of PRTX-100 in adult patients with persistent/chronic ITP (the “PRTX-100-203 Study”). In September 2015, the EMA Committee for Orphan Medicinal Products (COMP) issued a positive opinion recommending PRTX-100 for designation as an orphan medicinal product for the treatment of ITP. In November 2015, we enrolled our first patient in the PRTX-100-202 Study in the United States and in January 2016 we enrolled our first patient in the PRTX-100-203 Study in Europe. Enrollment has been completed in both the PRTX-100-202 Study in the U.S. and the United Kingdom (UK) and in the PRTX-100-203 Study in the UK during the past quarter. In August 2017, the FDA's Office of Orphan Product Development (OOPD) awarded us a grant of $403,000 to support the future clinical development of PRTX-100 as a treatment for ITP.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Birner Dental Management Services (BDMS) 9,898 3% -3.8 -22% 15,346 19,155 61,025 1,580 -3,376 -2,568 9,702
Bally (BLYQ) 9,850 -395.9 0 35 0 0 -25 -25 9,850
Deep Down (DPDW) 9,794 38% 35.3 -1% 23,435 6,617 15,966 6,068 -273 227 8,012
Tofutti Brands (TOFB) 9,793 28% -171.6 -2% 5,114 1,443 9,766 2,735 -79 -54 9,266
Intreorg Systems (IORG) 9,783 -20.4 -1,133% 46 3,194 0 0 -519 -477 9,737
Blue Dolphin Energy (BDCO) 9,768 2% 3.5 8% 70,540 70,152 225,905 5,604 5,615 12,188 42,739
Atlantica (ALDA) 9,761 -54.3 0 2,617 0 0 -246 -180 9,761
Bang Holdings (BXNG) 9,687 79% -24.2 -488% 88 1,476 180 141 -431 -398 9,654
Rex Energy (REXX) 9,530 0% 3.0 -13% 992,519 1,117,350 245,920 0 -129,799 -17,449 -52,356
Conversion Labs (CVLB) 9,520 76% 57.4 -10% 2,546 3,114 8,524 6,511 -266 165 9,462
Protalex (PRTX) 9,465 -2.3 -2,978% 156 2,846 0 0 -4,647 -4,064 9,350
Antilia Group (AGGG) 9,438 0% -388.0 -42% 58 65 1 0 -24 -24 9,438
Sports Field Holdings (SFHI) 9,433 18% -12.1 -68% 1,799 10,800 4,000 708 -1,225 -954 11,535
Sunnyside Bancorp (SNNY) 9,406 45.7 -0% 87,313 75,948 0 0 -201 180 8,212
PetroQuest Energy (PQ) 9,371 0% -0.8 -2% 232,925 158,177 63,115 0 -3,719 8,676 -7,310
Best Hometown Bancorp (BTHT) 9,295 0% 6.8 -1% 111,298 98,963 56 0 -905 600 4,062
Janel (JANL) 9,201 30% 8.8 1% 55,266 39,850 63,607 18,943 689 1,329 11,652
Wizard World (WIZD) 9,118 12% -7.1 -158% 789 6,791 8,923 1,073 -1,249 -1,249 8,804
Seychelle Environmental (SYEV) 9,058 51% 25.0 5% 4,366 877 2,700 1,386 220 276 6,883
Defense Technologies (DTII) 8,977 24.2 466% 80 3,121 0 0 371 371 8,975

Balance Sheet ($'000)2011-08-312011-11-302012-02-292012-05-312012-08-312012-11-302013-02-282013-05-312013-08-312013-11-302014-02-282014-05-312014-08-312014-11-302015-02-282015-05-312015-08-312015-11-302016-02-292016-05-312016-08-312016-11-302017-02-282017-05-312017-08-312017-11-302018-02-282018-05-312018-08-31
Cash97254287319058321,7042,4572,0191,0842,7161,6157586624609281,0156865954443917145814874772581,441555115
Accounts Receivable
Inventory
PP&E
Assets997630944241841251,7792,5062,0421,1752,7891,6667817705549891,0758086865034668817255975383941,550631156
Accounts Payable183183183183391784445672304274475413395800503495394883780562346553525489589507719428468
Long-Term Debt2,000
Liabilities1,2611,7602,9893,3644,3765,6918,64411,0039,6319,7929,8349,8509,87111,07712,05313,57814,60915,85416,88617,86018,91120,24621,35122,33723,44224,3032,7412,7312,846
Stockholders' Equity-264-1,131-2,045-3,124-4,293-5,566-6,865-8,497-7,589-8,617-7,045-8,184-9,090-10,308-11,499-12,588-13,534-15,046-16,200-17,356-18,444-19,365-20,626-21,740-22,905-23,909-1,191-2,100-2,690
Income Statement ($'000)2011-08-312011-11-302012-02-292012-05-312012-08-312012-11-302013-02-282013-05-312013-08-312013-11-302014-02-282014-05-312014-08-312014-11-302015-02-282015-05-312015-08-312015-11-302016-02-292016-05-312016-08-312016-11-302017-02-282017-05-312017-08-312017-11-302018-02-282018-05-312018-08-31
Revenue00000000000000000000000000000
Cost of Revenue
Gross Profit
R&D3544495145836758359851,3399336858377776159477426865371,064808728449476814645682548537513249
SG&A1795312813023142444263623736074,0082,7633,3803,0746906412,80579479776535894128174142153868332298
Tax000000000000000000000000000
Net Income-832-1,302-1,073-1,238-1,365-1,421-1,615-1,880-1,512-1,492-5,050-3,799-4,175-3,325-1,673-1,572-3,616-2,200-1,840-1,760-1,268-349-1,262-1,113-1,165-1,005-1,721-1,145-776
Cash Flow ($'000)2011-08-312011-11-302012-02-292012-05-312012-08-312012-11-302013-02-282013-05-312013-08-312013-11-302014-02-282014-05-312014-08-312014-11-302015-02-282015-05-312015-08-312015-11-302016-02-292016-05-312016-08-312016-11-302017-02-282017-05-312017-08-312017-11-302018-02-282018-05-312018-08-31
Cash Operating-570-430-670-682-1,133-825-1,528-1,247-1,438-9355,8951,102857-826-1,392-917948-1,018-1,127-1,186-1,148-713-1,113-964-880-562-935-441
Cash Investing0000000000000000000000
Cash Financing01,00001,0008003,2002,0001,0000007301,1901,3851,0356901,0351,0351,0951,0359808708701,745500